Your browser doesn't support javascript.
loading
Suicidality in treatment resistant depression: perspective for ketamine use.
Jakuszkowiak-Wojten, Katarzyna; Galuszko-Wegielnik, Maria; Wilkowska, Alina; Slupski, Jakub; Wlodarczyk, Adam; Górska, Natalia; Szarmach, Joanna; Szalach, Lukasz P; Wiglusz, Mariusz S; Krysta, Krzysztof; Cubala, Wieslaw Jerzy.
Afiliação
  • Jakuszkowiak-Wojten K; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Debinki St. 7 build. 25, 80-952 Gdansk, Poland, k.jakuszkowiak@gumed.edu.pl.
Psychiatr Danub ; 31(Suppl 3): 258-260, 2019 Sep.
Article em En | MEDLINE | ID: mdl-31488737
ABSTRACT
Suicidal ideations or attempts in patients with major depressive disorder (MDD) are emergent conditions that require immediate treatment. Numerous therapeutic interventions to reduce suicide risk in psychiatric disorders are effective in long-term suicide prevention, but there is necessity of sufficient, rapid pharmacological treatment of suicidal risk in MDD. Ketamine, an N-methyl-D-aspartate (NMDA) antagonist, has been reported to have rapid antidepressant effect. Depressive symptoms, anxiety, hopelessness, suicidal ideation had decreased within hours after ketamine infusion. Ketamine's rapid symptoms relief and reduction of suicide thoughts has aroused growing interests in psychiatric association.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Transtorno Depressivo Resistente a Tratamento / Prevenção do Suicídio / Ketamina Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Transtorno Depressivo Resistente a Tratamento / Prevenção do Suicídio / Ketamina Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article